U
U.S.-based biotechnology company developing antibody therapeutics for pathogenic antibody-mediated autoimmune and neuroinflammatory diseases. Its pipeline includes antibody candidates targeting FcRn and APRIL, alongside CNS-focused programs. Kaigene licenses early-stage candidates to pharmaceutical partners for further development and commercialization.